drugset / Trial / NCT03801499
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma
Timeline
- Start
- 2018-09-01
- Primary completion
- 2019-12
- Completion
- 2019-12
Outcome
Outcome not reported
Stopped: “Protocol modification”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |